IN2014DN10428A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10428A
IN2014DN10428A IN10428DEN2014A IN2014DN10428A IN 2014DN10428 A IN2014DN10428 A IN 2014DN10428A IN 10428DEN2014 A IN10428DEN2014 A IN 10428DEN2014A IN 2014DN10428 A IN2014DN10428 A IN 2014DN10428A
Authority
IN
India
Prior art keywords
disulfide bond
bridge
reacting
preparation
heavy chain
Prior art date
Application number
Other languages
English (en)
Inventor
John Burt
Antony Godwin
George Badescu
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1210838.7A external-priority patent/GB201210838D0/en
Priority claimed from GB201306706A external-priority patent/GB201306706D0/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of IN2014DN10428A publication Critical patent/IN2014DN10428A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN10428DEN2014 2012-06-19 2013-06-19 IN2014DN10428A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1210838.7A GB201210838D0 (en) 2012-06-19 2012-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
GB201306706A GB201306706D0 (en) 2013-04-12 2013-04-12 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/051593 WO2013190292A2 (fr) 2012-06-19 2013-06-19 Nouveau procédé de préparation de conjugués d'anticorps et nouveaux conjugués d'anticorps

Publications (1)

Publication Number Publication Date
IN2014DN10428A true IN2014DN10428A (fr) 2015-08-21

Family

ID=48699187

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10428DEN2014 IN2014DN10428A (fr) 2012-06-19 2013-06-19

Country Status (16)

Country Link
US (1) US20150125473A1 (fr)
EP (1) EP2861261A2 (fr)
JP (1) JP2015521615A (fr)
KR (1) KR20150023027A (fr)
CN (1) CN104379178A (fr)
AU (1) AU2013279099A1 (fr)
BR (1) BR112014031613A2 (fr)
CA (1) CA2876365A1 (fr)
HK (1) HK1204924A1 (fr)
IL (1) IL235646A0 (fr)
IN (1) IN2014DN10428A (fr)
MX (1) MX2014015682A (fr)
RU (1) RU2015101333A (fr)
SG (1) SG11201407600UA (fr)
WO (1) WO2013190292A2 (fr)
ZA (1) ZA201408916B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008376A2 (pt) * 2012-10-24 2017-09-26 Polytherics Ltd conjugados fármaco-proteína
NO2789793T3 (fr) * 2012-10-24 2018-01-27
EA038512B1 (ru) 2013-03-15 2021-09-08 Регенерон Фармасьютикалз, Инк. Конъюгаты майтанзиноидов и их терапевтическое применение
MX2016002149A (es) 2013-08-26 2016-10-28 Regeneron Pharma Composiciones farmaceuticas que contienen diasteromeros macrolidos, metodos para su sintesis y usos terapeuticos.
WO2015179734A1 (fr) * 2014-05-23 2015-11-26 Novartis Ag Procédés pour la fabrication ce conjugués à partir de protéines contenant des liaisons disulfures
EP3148592A2 (fr) * 2014-06-02 2017-04-05 Regeneron Pharmaceuticals, Inc. Conjugués de molécules biologiquement actives, réactifs et méthodes de fabrication, et utilisations thérapeutiques
SG11201700365TA (en) 2014-07-24 2017-02-27 Genentech Inc Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
JP2017534612A (ja) 2014-10-14 2017-11-24 ポリセリックス・リミテッド Ｐｅｇの部分を含めた脱離基を含む試薬を用いるペプチド又はタンパク質のコンジュゲーションのための方法
EP3220956B1 (fr) * 2014-10-24 2023-08-09 Abzena (UK) Limited Conjugués et réactifs de conjugaison
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
AU2015360724A1 (en) * 2014-12-08 2017-07-13 Sorrento Therapeutics, Inc. c-Met antibody drug conjugate
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
EP3262068A1 (fr) * 2015-02-05 2018-01-03 Ablynx N.V. Dimères nanobody liés par l'intermédiaire de cystéines d'ingénierie au niveau du c-terminal
EP3331569A1 (fr) 2015-08-07 2018-06-13 Gamamabs Pharma Anticorps, conjugués anticorps-médicaments et procédés d'utilisation
EP3165237B1 (fr) 2015-11-03 2018-12-19 Industrial Technology Research Institute Conjugué d'anticorps-médicament (adc) et son procédé de fabrication
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
EP3442595A1 (fr) * 2016-04-14 2019-02-20 Polytherics Limited Conjugués et réactifs de conjugaison comprenant un lieur qui comprend au moins deux motifs (-ch2-ch2-o-) dans un cycle
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
TWI763732B (zh) * 2016-11-07 2022-05-11 美商西雅圖遺傳學公司 工程化半胱胺酸帽之分佈
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
EP4110383A4 (fr) * 2020-02-26 2024-02-28 University of Maryland, College Park Compositions et méthodes de vaccination mucosale contre le sars-cov-2
WO2021115497A2 (fr) * 2020-12-08 2021-06-17 和铂医药(上海)有限责任公司 Conjugué protéine-médicament et procédé de conjugaison spécifique à un site

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP1817341A2 (fr) * 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
WO2009006520A1 (fr) * 2007-07-03 2009-01-08 Medimmune, Llc Ingénierie de domaine charnière
SG187517A1 (en) * 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2496521C2 (ru) * 2008-04-24 2013-10-27 Кантаб Байофармасьютикалз Патентс Лимитед Конъюгаты фактора ix с увеличенным временем полужизни
WO2011060018A2 (fr) * 2009-11-13 2011-05-19 Ikaria Development Subsidiary Two Llc Compositions et méthodes d'utilisation de peptides, de peptides modifiés, de pseudo-peptides, et de dérivés de fibrine
UY33827A (es) * 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
JP2015510877A (ja) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾

Also Published As

Publication number Publication date
WO2013190292A2 (fr) 2013-12-27
WO2013190292A3 (fr) 2014-03-20
AU2013279099A1 (en) 2014-12-18
US20150125473A1 (en) 2015-05-07
RU2015101333A (ru) 2016-08-10
ZA201408916B (en) 2015-11-25
CN104379178A (zh) 2015-02-25
SG11201407600UA (en) 2014-12-30
CA2876365A1 (fr) 2013-12-27
JP2015521615A (ja) 2015-07-30
MX2014015682A (es) 2015-07-23
IL235646A0 (en) 2015-01-29
KR20150023027A (ko) 2015-03-04
BR112014031613A2 (pt) 2017-07-25
EP2861261A2 (fr) 2015-04-22
HK1204924A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
IN2014DN10428A (fr)
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
MX2013009362A (es) Anticuerpo contra el csf-1r.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
GB201103836D0 (en) Conjugation process
HK1254782A1 (zh) 半胱氨酸工程化抗體的結合物
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
NZ701040A (en) Covalently linked antigen-antibody conjugates
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
CO7111294A2 (es) Anticuerpo anti-fgfr2
MX2016008189A (es) Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
CY1121944T1 (el) Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus
MX2015003541A (es) Metodos para identificar los anticuerpos con inmunogenia reducida.
IL272561A (en) Antibodies with modified FC variants to increase half-life in the blood
WO2012047941A3 (fr) Polypeptides de l'hémagglutinine, et réactifs et procédés associés à ceux-ci
MX350335B (es) Anticuerpos que enlazan alfa-v beta-8 integrina.
NZ629072A (en) Compositions comprising secretory - like immunoglobulins
EA201491959A1 (ru) Агонистические пептиды для par4
WO2013115410A3 (fr) Anticorps dirigé contre la phospholipase d4
WO2012149334A3 (fr) Procédés et compositions pour préparer et utiliser des anticorps spécifiques à une conformation
EA201290804A1 (ru) Способ активации и сопряжения биомолекул